First-in-human global multi-center study of RLY-2608, a pan mutant and isoform selective PI3Kα inhibitor, as a single agent in advanced solid tumor patients and in combination with fulvestrant in patients with advanced breast cancer
Download
03
Our DynamoTM platform and approach are creating new possibilities in drug discovery
Program
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
RLY-4008
FGFR2
RLY-2608
PI3KαPAN
RLY-5836
PI3KαPAN
CDK2 Inhibitor
ERα Degrader
RLY-1971
SHP2
Discovery Programs (5+)
While our initial focus has been on enhancing small molecule therapeutic discovery in precision oncology, protein conformational dynamics are implicated in a wide variety of therapeutic areas. We have also leveraged the power of our Dynamo platform to extend to genetic disease as well.
Our current discovery programs are focused in targeted oncology (3) and genetic disease (2).
We also continue to evaluate potential additional therapeutic areas beyond precision oncology and genetic disease that we could enter in the future.
Publications/
Presentations
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
At Relay Therapeutics, we know that patients need new medicines now. This is the driving force behind everything we do.